Renhe Pharmacy Co Ltd

Renhe Pharmacy maintains a strong liquidity position, with a current ratio of 6.48, indicating the company can easily cover its short-term obligations. The company's debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal reliance on debt financing. Free cash flow of 316.42 million CNY supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity of 6.23% and a return on assets of 5.08%, which are in line with the industry's median performance for pharmaceutical firms. The company's net income of 393.21 million CNY and operating income of 661.51 million CNY reflect a healthy margin structure, though gross profit of 1.30 billion CNY suggests moderate cost control. Geographically, Renhe Pharmacy's revenue is concentrated in China, with no disclosed international operations. The company's business is segmented into pharmaceutical development, manufacturing, and distribution, though no specific segment revenue breakdown is available in the latest financials. Looking ahead, the company is expected to grow revenue to 3.82 billion CNY in the next fiscal year, a 7.97% increase from the current year's 3.54 billion CNY. Analysts also project an EPS of 0.29 CNY, indicating a stable earnings outlook. The risk assessment highlights a medium liquidity risk due to negative net cash after subtracting total debt, and a low dilution risk with no near-term pressure from share issuance. The company's capital expenditure of -74.59 million CNY suggests a reduction in investment in physical assets, which may reflect a shift toward cost optimization. Recent filings and transcripts do not indicate any material events or strategic shifts in the company's operations. The business remains focused on its core pharmaceuticals segment, with no disclosed expansion into new therapeutic areas or markets.